Department of Internal Medicine, University of Toledo, Toledo, OH, USA.
Department of Internal Medicine, University of Louisville, Louisville, KY,USA.
Hosp Pract (1995). 2024 Aug;52(3):84-90. doi: 10.1080/21548331.2024.2337615. Epub 2024 Apr 2.
Heart failure is a pressing public health concern, affecting millions in the United States and projected to rise significantly by 2030. Iron deficiency, prevalent in nearly half of ambulatory heart failure patients, contributes to anemia and diminishes patient outcomes. In this study, we aim to evaluate the impact of iron deficiency anemia on acute heart failure hospitalizations outcomes.
Utilizing the 2019 National Inpatient Sample (NIS) database, a retrospective observational study assessed 112,864 adult patients hospitalized with heart failure and 7,865 cases also had a concomitant diagnosis of iron deficiency anemia (IDA).
Among 112,864 heart failure hospitalizations in 2019, approximately 7% had concomitant iron deficiency anemia (IDA). Heart failure patients with IDA exhibited distinct demographic characteristics, with females comprising 51.1% ( < 0.01) and higher rates of complicated hypertension ( < 0.01), complicated diabetes ( < 0.01), and peripheral vascular disease ( < 0.01). Adjusted mean LOS for patients with IDA was significantly longer at 1.31 days (95% CI 0.71-1.47; < 0.01), persisting in both HFpEF and HFrEF subgroups. While total hospital charges were comparable in HFpEF, HFrEF patients with IDA incurred significantly higher charges ($13427.32, 95% CI: 1463.35-$25391.29, = 0.03) than those without IDA. Complications such as atrial fibrillation and acute kidney injury were notably more prevalent in HFpEF and HFrEF patients with IDA.
The study highlighted that iron deficiency in heart failure patients leads to extended hospital stays, increased costs, and heightened risks of specific complications, particularly in HFrEF. Our study emphasized the implications of IDA in patients with heart failure ranging from prolonged hospitalizations and increased costs. Addressing iron deficiency is crucial, given its substantial impact on heart failure hospitalizations and outcomes, emphasizing the need for proactive diagnosis and management.
心力衰竭是一个紧迫的公共卫生问题,影响了美国数以百万计的人,预计到 2030 年将显著上升。缺铁在近一半的门诊心力衰竭患者中很常见,导致贫血并降低患者的预后。在这项研究中,我们旨在评估缺铁性贫血对急性心力衰竭住院结局的影响。
利用 2019 年全国住院患者样本(NIS)数据库,进行了一项回顾性观察性研究,评估了 112864 名因心力衰竭住院的成年患者和 7865 例同时诊断为缺铁性贫血(IDA)的患者。
在 2019 年的 112864 例心力衰竭住院患者中,约有 7%同时患有缺铁性贫血(IDA)。IDA 心力衰竭患者具有明显的人口统计学特征,女性占 51.1%( < 0.01),并伴有更高的复杂高血压( < 0.01)、复杂糖尿病( < 0.01)和外周血管疾病( < 0.01)的发病率。IDA 患者的调整后平均 LOS 显著延长至 1.31 天(95%CI 0.71-1.47; < 0.01),在 HFpEF 和 HFrEF 亚组中均如此。虽然在 HFpEF 中总住院费用相当,但 IDA 心力衰竭患者的费用明显更高($13427.32,95%CI:1463.35-$25391.29, = 0.03)。在 HFpEF 和 HFrEF 患者中,IDA 患者更常见心房颤动和急性肾损伤等并发症。
该研究表明,心力衰竭患者的缺铁会导致住院时间延长、成本增加以及特定并发症的风险增加,尤其是在 HFrEF 患者中。我们的研究强调了 IDA 对心力衰竭患者从延长住院时间和增加成本的影响。鉴于缺铁对心力衰竭住院和结局有重大影响,因此解决缺铁问题至关重要,这强调了积极诊断和管理的必要性。